Twenty-eight epithelial and 22 nonepithelial feline tumors were studied immunohistochemically. Epithelial tumors were 10 squamous cell carcinomas, two basal cell tumors, two sebaceous gland carcinomas, three apocrine gland carcinomas, three thyroid papillary carcinomas, one thyroid solid carcinoma, one renal clear cell carcinoma, one renal papillary carcinoma, one endometrial carcinoma, and four lung bronchioloalveolar carcinomas. Nonepithelial tumors were 10 fibrosarcomas, one liposarcoma, one leiomyosarcoma, one rhabdomyosarcoma, one hemangiosarcoma, two mast cell tumors, one osteosarcoma, three melanomas, and two lymphomas. Commercially available antibodies directed against high-and low-molecular-weight keratins (keratin, RCK-102, NCL-5D3), vimentin, desmin, glial fibrillary acidic protein (GFAP), and neurofilament intermediate filament (IF) proteins were used in the avidin-biotin-peroxidase complex technique on formalin-fixed, paraffin-embedded tumor tissue samples. All epithelial tumors except the endometrial carcinoma expressed some type of keratin protein. Squamous cell carcinomas expressed high-molecular-weight keratins exclusively. Coexpression of high-and low-molecular-weight keratins was observed in one basal cell tumor, sebaceous and apocrine adenocarcinomas, and thyroid, renal, and lung carcinomas. In addition to keratins, vimentin immunoreactivity was found in all basal cell tumors, all sebaceous gland, thyroid papillary, renal, and lung adenocarcinomas, and one of the apocrine gland adenocarcinomas. Immunoreactivity with GFAP antibody was found in one basal cell tumor and one sebaceous gland adenocarcinoma. The endometrial carcinoma did not react with any of the antibodies applied. Nonepithelial tumors analyzed expressed either vimentin (fibrosarcomas, liposarcoma, haemangiosarcoma, mast cell tumors, osteosarcomas, melanomas) or vimentin and desmin (leiomyosarcoma, rhabdomyosarcoma, one fibrosarcoma) IF proteins exclusively. Lymphomas did not react with any of the antibodies employed. These findings indicate that IF proteins antibodies can be included in diagnostic panels of antibodies for immunocharacterization of feline tumors. In addition, they can be used as a basis for the diagnoses of poorly differentiated or undifferentiated feline neoplasms.
In this study, the expression and distribution patterns of keratin, vimentin, desmin, GFAP, and NF IF proteins have been analyzed in a wide range of welldifferentiated and moderately differentiated feline neoplasms using commercially available monoclonal and polyclonal antibodies and immunohistochemical techniques on routinely processed tumor tissue samples.
Materials and Methods

Tissue preparation
Twenty-eight epithelial and 22 nonepithelial tumors were examined (Tables 1, 2). Cutaneous epithelial tumors were classified histologically60 as follows: squamous cell carcinoma (1 0), basal cell tumor (2) , sebaceous gland adenocarcinoma (2) , and apocrine gland adenocarcinoma (3). In addition, the following noncutaneous epithelial tumors were studied: papillary thyroid carcinoma (3), solid thyroid carcinoma (l), renal solid clear cell carcinoma (l), renal papillary adenocarcinoma ( 1 ), well-differentiated endometrial adenocarcinoma (l), and bronchioloalveolar carcinoma (4). Nonepithelial tumors of the skin and soft tissues were classified histologically60 as follows: fibrosarcoma (8), liposarcoma (l), leiomyosarcoma (l), rhabdomyosarcoma (l), mast cell tumor (2) , and melanoma (1) . Tumors of bone were classified as fibrosarcoma (2) and osteosarcoma (l), and one intraocular tumor was a melanoma. In addition, three histologic types of tumors were found in lung, liver, and spleen (one melanoma); liver and spleen (one hemangiosarcoma); and lymph nodes, spleen, and liver (two lymphomas). The tumor tissue samples were submitted as surgical excision specimens in 10% buffered formalin. Fixation time, although uncertain, was probably 24-48 hours in most cases. Tumor tissue samples were embedded in paraffin, and sections were cut at 4 wm. 
Antibodies
Three commercially available antibodies (Eurodiagnostics B.V., Apeldoorn, The Netherlands) were used to analyze keratin IF.
phosphate-buffered saline, pH 7.6. Nonaltered routinely processed feline tissues were used as positive controls for all antibodies e m p l~y e d .~~.~~ Anti-keratin is a polyclonal antibody (PAB) (affinity purified IgG) developed in rabbit against human skin cells. Its specificity has been tested by immunohistochemistry. It was used at a dilution of 1 : 150. RCK-102 is a monoclonal antibody (MAB) developed against human lung cancer cells. It has been characterized by immunoblotting and reacts with the 58-kd and 52.2kd keratin proteins (numbers 5 and 8, respectively, in the Moll catalog~e~~). Immunohistochemistry on frozen and paraffin sections, cell lines, and cytologic specimens has also been used as a screening method. RCK-102 was used at a dilution of 1 : 20. NCL-5D3 is a MAB developed against human breast carcinoma cell line MCF 7. It has been characterized by immunoblotting and reacts with the 52.2-kd, 45-kd, and 40-kd keratin proteins (numbers 8, 18, and 19, respectively, in the Moll catalogue40). NCL-5D3 was used at a dilution of 1 : 20.
In addition, commercially available PABs (Eurodiagnostics B.V.) directed against calf lens vimentin, chicken gizzard desmin, and human spinal cord GFAP and a MAB directed against human brain NF proteins were employed. Polyclonal antibodies were used at a dilution of 1 : 150, and the MAB NF antibody was diluted 1 : 20.
Immunohistochemical staining
The avidin-biotin complex (ABC) method (Vector, Burlingame, CA) was used with both the PABs and MABs as previously described." Predigestion of tissue sections for 10 minutes with 0.1% pronase (Sigma Chemical Co., St. Louis, MO) was employed with the RCK-102 and NCL-5D3 M A B s .~~ The biotinylated swine anti-rabbit immunoglobulin (Vector) (prediluted) and goat anti-mouse immunoglobulin antibodies (Nordic Immunological Laboratories, Tilburg, The Netherlands) diluted 1 : 20 were incubated for 30 minutes and the ABC for 60 minutes, both at room temperature. The chromogen, 0.5% 3,3'-diaminobenzidine tetrahydrochloride (Sigma Chemical Co.) diluted 1 : 10 in 0.05 M Tris containing 0.3% H,Oz, was applied to the slides for 2-3 minutes at 20-22 C. Slides were counterstained with Mayer's haematoxylin. Negative controls included substituting the primary specific reagents with either rabbit and mouse nonimmune sera or
Results
Epithelial tumors
All tumors, with the exception of the endometrial adenocarcinoma, expressed some of the keratin IF proteins detected by the antibodies employed, and some of them coexpressed either keratin and vimentin, or keratin, vimentin, and GFAP IF proteins.
All cutaneous epithelial tumors (Table 1) reacted with both keratin PAB and RCK-102 (keratins M5 + M8) MAB. In squamous cell carcinomas, the pattern of staining with both antibodies varied according to the degree of differentiation of the neoplasm. Keratin PAB reacted with more differentiated cells ( Fig. 1 ) either grouped at the center of tumor nests or randomly distributed throughout the neoplastic growth, whereas RCK-102 MAB reacted with the more basal cells of the tumor nests ( Fig. 2 ) and diffusely in moderately differentiated tumors. The staining reaction in basal cell tumors and in sebaceous gland and apocrine gland carcinomas was more widely distributed and stronger with RCK-102 MAB than with keratin PAB. One of the two basal cell tumors and one of the apocrine gland carcinomas also reacted with NCL-5D3 (keratins M8 + M 1 8 + M 1 9) MAB. Immunoreactivity was found in cells lining cystic structures exclusively in the cystic basal cell tumor and was difise and of high intensity in the apocrine adenocarcinoma ( Fig. 3) . Normal counterparts were also stained by this antibody, although basal cells in the epidermis reacted in an heterogeneous fashion.
In addition to keratins, vimentin immunoreactivity was found in both basal cell tumors and sebaceous gland adenocarcinomas and in one apocrine gland carcinoma (Table 1 ). In the solid basal cell tumor, cells reacting with the vimentin PAB outnumbered those reacting with any of the keratin antibodies (Fig. 4) , and in the other tumors, the number of reactive cells was large. Vimentin-positive cells were randomly distributed and otherwise indistinguishable from their nonreactive counterparts. Immunoreactivity to vimentin was observed in basal cells of isolated hair follicles but not in sebaceous glands.
Immunoreactivity with GFAP PAB was also found in the solid basal cell tumor ( Fig. 5 ) and in one of the sebaceous gland adenocarcinomas ( Table 1 ). The number of reactive cells was small in both types of tumors, and they were frequently found at the epithelial-stro-ma1 junction in a palisading position in the basal cell tumor. These GFAP-positive cells also reacted with the vimentin PAB. Immunoreactivity with GFAP PAB was not observed in nonneoplastic tissues. Additionally, some scattered cells reacted with desmin PAB in the same sebaceous gland adenocarcinoma.
Thyroid papillary carcinomas, renal clear cell and tubulopapillary carcinomas, and all histologic types of pulmonary carcinomas coexpressed keratins and vimentin. The thyroid solid carcinoma expressed keratins exclusively, and the cells of the endometrial carcinoma did not react with any of the antibodies applied however, internal controls were weakly positive. Immunoreactivity with keratin PAB was exclusively found in solid nests and tubular structures at the periphery of the thyroid carcinomas; cells in papillae were unreactive. No keratin-PAB-immunoreactive cells were found in the solid thyroid carcinoma. Keratin-PABpositive cells were scarce in the renal clear cell carci-noma, where they were grouped in solid nests among the sheets of clear cells ( Fig. 6 ) and in the tubulopapillary carcinoma. In bronchioloalveolar carcinomas, staining with keratin PAB was weak and scarce with the exception of cells with squamous metaplasia, which were present in one of the tumors. RCK-102 MAB reaction ( Fig. 6 ) was stronger and of wider distribution than that obtained with either keratin antibody or NCL-5D3 MAB in all cases, whereas vimentin PAB immunoreactivity was either abundant (renal clear cell carcinoma, one of the bronchioloalveolar carcinomas) ( Fig. 7) or scarce (bronchioloalveolar carcinomas) and heterogeneous.
Nonepithelial tumors
All nonepithelial tumors studied reacted with vimentin PAB, with the exception of lymphomas, which were not stained by any of the antibodies employed ( Table 2 ). In addition, one leiomyosarcoma, one rhabdomyosarcoma, and one of the tumors diagnosed as fibrosarcoma reacted with desmin PAB. No tumors of this group reacted with antibodies to keratins or GFAP.
The pattern of staining with vimentin PAB was different in individual cases: more than half of the tumor cells were stained in the majority of fibrosarcomas ( Fig. 8 ) and in the hemangiosarcoma, but the number of positive cells in the other nonepithelial tumors was lower. Desmin PAB immunoreactivity was weak and scarce in the leiomyosarcoma and stronger and more widely distributed in the rhabdomyosarcoma analyzed ( Fig. 9 ). Vimentin-positive cells outnumbered desminpositive cells in both muscle tumors, a situation similar to that found in a moderately differentiated fibrosarcoma, which presented scarce, rounded, or elongated desmin-positive cells.
Discussion
Accurate classification of tumors by routine histologic examination may be difficult or even impossible in undifferentiated tumors and in small tumor tissue fragments. Immunohistochemical evaluation of tumor markers can contribute to accurate classification.
Intermediate filaments share antigenic determinants among mammalian species; cross-reactivity of IF antibodies among these species is widely known. 14,23,57,58 A prerequisite for the use of a particular IF protein antibody as a tumor marker in undifferentiated neoplasms of a given species is the knowledge of its distribution pattern in both healthy tissues and neoplasms of that particular species. The immunohistochemical distribution pattern of the IF antibodies employed in this study was previously analyzed in nonneoplastic feline t i s s~e s .~~,~~ Analysis of the immunohistochemical distribution pattern of IF proteins in a series of 50 routinely processed feline tumor tissue samples using those IF protein MABs and PABs has shown that all epithelial tumors with the exception of endometrial carcinoma expressed some type of keratin IF proteins and that all nonepithelial tumors expressed vimentin IF protein, with the exception of lymphomas. In addition, some epithelial tumors coexpressed either keratin and vimentin, or keratin, vimentin, and GFAP IF proteins, whereas muscle cell tumors and one of the tumors diagnosed as a fibrosarcoma coexpressed vimentin and desmin IF proteins.
None of the keratin antibodies employed reacted with all epithelial tumors, which emphasizes the difficulty already noticed in several neoplasms series of different species3,5,9,13.23,45 of obtaining a panepithelial marker. However, RCK-102 MAB appeared to be the widest marker of feline epithelial neoplasms. Squamous cell carcinomas (five well-differentiated and five moderately differentiated tumors) expressed high-molecular-weight keratins exclusively, and the pattern of Martin de las Mulas, Espinosa de 10s Monteros, Carrasco, van Niel, and Fernandez Vet Pathol 3216, 1995 staining with keratin antibody and RCK-102 MAB closely mimicked that of normal feline squamous epithelium, the former recognizing more differentiated cells and the latter recognizing less differentiated cells.34 Squamous cell carcinomas in humans are known to express keratins M5, M6, M14, and M16.43 In addition, a variable percentage of fusiform cell and undifferentiated squamous cell carcinomas in humans express low-molecular-weight (M8, M 18, M 19) and ~i m e n t i n .~,~~~~* Also, in the dog one squamous cell carcinoma reacted with both vimentin PAB and MAB, but the degree of differentiation of this tumor is not known3 None of the tumors examined were of the fusiform cell type or undifferentiated, which suggests that the preservation of the nonneoplastic immunophenotype is higher in well-differentiated neoplastic growths.
Both basal cell tumors analyzed coexpressed highmolecular-weight keratins and vimentin; the cystic tumor also expressed low-molecular-weight keratins, and the solid one also expressed GFAP. Although the number of basal cell tumors analyzed is low, these tumors show an IF immunophenotype different from that previously described in other species. Basal cell tumors express high-and low-molecular-weight keratins in and dogs,3 but coexpression with other IF proteins has not been reported. In addition to keratins, the adnexal tumors analyzed also expressed vimentin (one apocrine gland carcinoma and one sebaceous gland carcinoma) or vimentin, GFAP, and desmin IF proteins (one sebaceous gland carcinoma). Feline apocrine gland carcinomas expressed highmolecular-weight keratins in an homogeneous fashion, whereas coexpression of high-and low-molecularweight keratins and vimentin was exclusively found in one of the tumors. Sweat gland tumors in humans and dogs express high-and low-molecular-weight kerat i n~.~~,~~,~~,~~,~~ In the dog, both luminal epithelial and myoepithelial neoplastic cells express keratins M6 and M 19, and the latter also express vimentin IF proteins.I7
Basal cell tumors arise from the bazal cell layer of the epidermis, hair follicles, sebaceous glands, sweat glands, or perhaps from embryonal cells in the dermis. These cells will differentiate into hair follicle tumors, sebaceous gland tumors, or sweat gland Immunoreactivity with vimentin antibody has been found in the basal layer of hair follicle e~i t h e l i a l .~~ If basal cell tumors analyzed in this study had originated from these structures, their immunophenotype would reflect that of nonneoplastic counterparts. In addition, embryonal cells express vimentin prior to the acquisition of keratin IF and the expression of vimentin in basal cell tumors would thus be an expression of the undifferentiated nature of the tumor cells. However, IF proteins share several peptides, and cross-reactivity may represent a problem, particularly between keratin and vimentin IF GFAP immunoreactivity in basal cell tumors and adnexal tumors is an unexpected finding. Although cross-reactivity with epitopes recognized by either keratin or vimentin antibodies cannot be ruled out, basal/myoepithelial cells in ducts and acini of complex glandular epithelia, particularly salivary and mammary glands, express GFAP depending on their stage of proliferation and differentiation.20,51%58 Nonaxonal staining in the peripheral nervous system with GFAP antibodies has been attributed to cross-reactivity of a cytoplasmic antigen of Schwann cells with GFAP antibody.61 Desmin immunoreactivity has not been reported in sebaceous gland adenocarcinomas of any species, although it has been observed in cytologic smears of canine basal cell and hair follicle tum01-s.~ Desmin is a very specific marker of muscular differentiation, but aberrant expression has been reported in isolated case^.^^,^^ Tumors derived from simple epithelia express lowmolecular-weight keratins as do their nonneoplastic cells of origin,L5,43,48 but coexpression of high-molecular-weight keratins and vimentin are well known in particular types of human tumors. 14, 15, 21, 27, 28, 30, 43, 48 In our study, papillary thyroid carcinomas coexpressed high-and low-molecular-weight keratins and vimentin, albeit the expression of high-molecular-weight keratins and vimentin was rather heterogeneous and the solid carcinoma did not express vimentin. These findings are in accordance with those previously reported in h u m a n~.~J~.~~ Renal cell tumors in humans, particularly tubulopapillary and clear cell carcinomas, coexpress low-molecular-weight (M8, M18, M 19) keratins and vimentin IF p r~t e i n~.~~,~~,~~,~~,~~ The expression of vimentin has been attributed to reexpression of this IF protein in neoplastic cells because vimentin is present in tubular epithelium during fetal development. 22 In the cat, adult tubular epithelium of collecting ducts coexpresses low-molecular-weight keratins (M8, M18, M19) and ~i r n e n t i n .~~.~~ Lung carcinomas in human^^,^^,^* and dogs9 must frequently express keratins M7, M8, M18, and (to a lesser extent) M19, although stratified epithelium-type keratins have also been found in human cases.21 In our study, bronchioloalveolar carcinomas coexpressed high-and low-molecular-weight keratins. The patterns of staining with NCL-5D3 and RCK-102 MABs and keratin PAB were different in that the two latter mainly stained tumor cells with squamous metaplasia, as has been described in the cat. 24 The expression of vimentin in a low number of neoplastic cells is also widely known in human and canine lung c a~c i n o r n a s .~J~J~ All nonepithelial tumors analyzed, with the exception of lymphomas, expressed vimentin IF proteins (Table 2) , as has already been described in correspond-ing types of tumors in humans, dogs, and sidered the most sensitive marker of striated muscular differentiati~n,',~,~~,~~,~~,~~ but its sensitivity is lower in smooth muscle
The feline muscle tumors analyzed coexpressed desmin and vimentin IF proteins, as is widely known in other species, including cats. 14,35, 39 The expression of vimentin in muscle tumors has been attributed to the regression of tumor cells to embryonal stages of differentiati~n.'~.~~ Given the high specificity of desmin for muscular differentiation, the immunoreactivity observed in one of the fibrosarcomas probably reflects the myogenic nature of the tumor. This situation with feline fibrosarcomas showing unexpected staining with desmin PAB has already been described.3s
The lack of staining of lymphomas with the vimentin antibody is in accordance with our findings in normal feline tissues using the same a n t i b~d y ,~~,~~ where lymphocytes were also nonreactive. Lack of staining of lymphocytes and lymphomas with vimentin antibodies has also been described in other specie^.^,^^
Our results show that the immunohistochemical distribution pattern of IF proteins in well-differentiated feline tumors is both similar and dissimilar to distribution patterns in other species and can be used as a basis for the diagnoses of poorly differentiated or undifferentiated neoplasms. cats. 3,9,11,12,14,26,27,35,41,43,46,57 Desmin expression is con-
